{
    "clinical_study": {
        "@rank": "77397", 
        "arm_group": [
            {
                "arm_group_label": "Phase 1", 
                "arm_group_type": "Experimental", 
                "description": "PF-03084014 in combination with gemcitabine and nab-paclitaxel"
            }, 
            {
                "arm_group_label": "Phase 2 Arm A", 
                "arm_group_type": "Experimental", 
                "description": "PF-03084014 in combination with gemcitabine and nab-paclitaxel"
            }, 
            {
                "arm_group_label": "Phase 2 Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine plus nab-Paclitaxel"
            }
        ], 
        "brief_summary": {
            "textblock": "This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and\n      the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel\n      followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of\n      overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously\n      treated with anticancer therapies."
        }, 
        "brief_title": "Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Cancer Pancreas", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the\n             pancreas.\n\n          -  No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic\n             disease. Prior adjuvant therapy with 5-FU or gemcitabine administered as\n             radiosensitizer allowed, provided at least 6 months have elapsed between the last\n             dose and study registration\n\n          -  Tumor tissue available (Archival 6 months old or de novo biopsy)\n\n          -  Measurable disease as per RECIST 1.1\n\n          -  Performance Status (ECOG) 0 or 1\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastases requiring steroids\n\n          -  Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor\n\n          -  Major surgery within 4 weeks of registration in the current study\n\n          -  Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients\n\n          -  Current or anticipated need for food or drugs that are strong/moderate CYP3A4\n             inhibitors or inducers\n\n          -  Diagnosis of any second malignancy within 3  years prior to registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "193", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109445", 
            "org_study_id": "A8641019"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase 1", 
                "description": "Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID", 
                "intervention_name": "PF-03084014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase 1", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase 1", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.", 
                "intervention_name": "Nab-paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }, 
            {
                "arm_group_label": "Phase 2 Arm A", 
                "description": "Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.", 
                "intervention_name": "PF-03084014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase 2 Arm A", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase 2 Arm A", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.", 
                "intervention_name": "Nab-paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }, 
            {
                "arm_group_label": "Phase 2 Arm B", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase 2 Arm B", 
                "description": "Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.", 
                "intervention_name": "Nab-paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8641019&StudyName=Study%20Of%20PF-03084014%20In%20Combination%20With%20Gemcitabine%20And%20Nab-Paclitaxel%20In%20Patients%20With%20Metastatic%20Pancreatic%20Adenocarcinoma%20Not%20Previously%2"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1/2 Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "First cycle dose limiting toxicity", 
                "measure": "Number of participants with Dose-limiting toxicities (DLT) - Phase 1", 
                "safety_issue": "Yes", 
                "time_frame": "From Cycle 1 Day 1 up to Cycle 1 Day 28."
            }, 
            {
                "description": "Overall survival is the difference in days between the date of death and the date of randomization.", 
                "measure": "Overall Survival (OS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "From the date of randomization, every 3 months until death for 30 months."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109445"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Only for subjects who achieved a CR or PR as per RECIST 1.1. DR is the time in days between the first date of first documentation of objective tumor response (CR or PR) and the date of tumor progression or death due to any cause whichever occurred first.", 
                "measure": "Duration of Response (DR) - Phase 1 and 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on treatment every 8 weeks from the first occurrence of  objective response, until disease progression or death, up to 12 months"
            }, 
            {
                "description": "Number of patients who achieved a CR or PR as per RECIST 1.1", 
                "measure": "Objective Response (OR) - Phase 1 and 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on treatment every 8 weeks until progression and at the end of treatment (up to 12 months)"
            }, 
            {
                "description": "Number of alive patients at 1 year from the date of randomization.", 
                "measure": "1-year Overall Survival (1yr-OS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "From the date of randomization, every 3 months until death up 12 months."
            }, 
            {
                "description": "Number of alive patients at 2 years from the date of randomization.", 
                "measure": "2-year Overall Survival (2yr-OS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "From the date of randomization, every 3 months until death up to 24 months."
            }, 
            {
                "description": "PFS is defined as the difference in days between the first date that criteria for progression was met or the patient died due to any cause and the date of randomization.", 
                "measure": "Progression Free Survival (PFS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on treatment every 8 weeks and at the end of treatment up to 12 months."
            }, 
            {
                "description": "BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.", 
                "measure": "Brief Pain Inventory-Short Form (BPI-sf)  - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months."
            }, 
            {
                "description": "QTc duration", 
                "measure": "QTc interval - Phase 1 and 2", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Cycle 1 Days 1 or 3 and 21. From cycle >1 on Day 1 and at the end of treatment up to 12 months."
            }, 
            {
                "description": "For PF-03084014", 
                "measure": "Maximum Plasma Concentration (Cmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 & 21 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose).  Day 1 of Cycles 2 & 3 (pre-dose and 1 hr after the morning dose)."
            }, 
            {
                "description": "For PF-03084014", 
                "measure": "Time to Maximum Plasma Concentration (Tmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 & 21 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose).  Day 1 of Cycles 2 & 3 (pre-dose and 1 hr after the morning dose)."
            }, 
            {
                "description": "For PF-03084014", 
                "measure": "Area Under the Plasma Concentration versus time curve (AUC) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 & 21 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose).  Day 1 of Cycles 2 & 3 (pre-dose and 1 hr after the morning dose)."
            }, 
            {
                "description": "For nab-paclitaxel", 
                "measure": "Maximum Plasma Concentration (Cmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 & 48 hrs after the start of infusion."
            }, 
            {
                "description": "For nab-paclitaxel", 
                "measure": "Time to Maximum Plasma Concentration (Tmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 & 48 hrs after the start of infusion."
            }, 
            {
                "description": "For nab-paclitaxel", 
                "measure": "Area Under the Plasma Concentration versus time curve (AUC) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 & 48 hrs after the start of infusion."
            }, 
            {
                "description": "For gemcitabine", 
                "measure": "Maximum Plasma Concentration (Cmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 ( pre-dose, 0.25,  0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion."
            }, 
            {
                "description": "For gemcitabine", 
                "measure": "Time to Maximum Plasma Concentration (Tmax) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 ( pre-dose, 0.25,  0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion."
            }, 
            {
                "description": "For gemcitabine", 
                "measure": "Area Under the Plasma Concentration versus time curve (AUC) - Phase 1", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days 1 & 15 ( pre-dose, 0.25,  0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion."
            }, 
            {
                "measure": "European Quality of Life Questionnaire (EQ-5D) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months."
            }, 
            {
                "measure": "European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC-QLQ-C30) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months."
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "Academic GI Cancer Consortium", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}